Dr. Olderman Highlights the Value of a Bonded Antimicrobial at Textiles Conference
Gainesville, Florida – February 1, 2008 -Quick-Med Technologies’ Vice President
of Research & Development and Commercialization, Gerald M. Olderman, Ph.D.,
presented “Unique and New: A Bonded Antimicrobial Concept,” at the recent Summit
Session on Antimicrobials in Plastic and Textile Applications Conference.
Dr. Olderman’s presentation showcased the multiple advantages of Quick-Med
Technologies’ patented NIMBUS® antimicrobial technology and emphasized the
uniqueness of a bonded antimicrobial.
NIMBUS is the only commercially available antimicrobial technology in which a large,
multi-active polymer is permanently bonded to any of a number of base materials.
NIMBUS is an acronym for Novel Intrinsic Micro-Bonded Utility Substrate.
Ordinary commercial antimicrobials work by “releasing” or “leaching” their active
agents. Sooner or later, this results in depletion of the agent which has several significant
drawbacks including loss of antimicrobial protection and an increase in likelihood of
spawning antimicrobial resistance (i.e. so called “super bugs”) as levels drop below the
levels needed for effective microbial kill rates. Because NIMBUS is permanently bonded
and does not deplete, it will not fall below the level needed to achieve inactivation (kill
microbes) and thus avoids the potential for bacteria to develop a resistance.
Studies conducted by the company, as well as by independent laboratories, demonstrate
that NIMBUS is highly effective, including against Methicillin-resistant Staphylococcus
aureus (“MRSA”) and Vancomycin-resistant Enterococcus (“VRE”), two of the most
significant antibiotic-resistant organisms responsible for hospital-acquired and
community-acquired infections.
Previous attempts to offer a “bonded” antimicrobial have been limited to small molecules
which are not capable of the strong permanent bonding achieved by NIMBUS. These
prior materials can be adequate for short-duration uses where strong, long-lasting
performance is not required. However, the relatively small size of the molecule means
that they are also prone to being blinded or otherwise loosing effectiveness in high
challenge applications.
The powerful breakthrough NIMBUS® antimicrobial technology offers many other
benefits that arise out of its permanence on the substrate. Because it remains at a fixed
level of concentration, it especially lends itself to reusability and repeated launderability,
even high levels of commercial or industrial laundering. NIMBUS is well suited for the
many applications where persistent, extended action is required such as apparel for
underwear, t-shirts to high performance textiles as well as commercial and military
uniforms, medical apparel, hospitals, hotel and hospitality industries. Additionally, it is
well suited for medical devices and other consumer products. And because NIMBUS
was originally developed for wound care applications, it maintains its effectiveness in the
presence of blood, body fluids and other “high-challenge” situations. It is a low cost
solution to many commercial requirements for a versatile product that can be customized
to meet customer needs.
Another benefit of the permanence of NIMBUS technology in would care applications is
the fact that because it is not free to migrate it cannot enter a wound and interfere with
healing. It provides safe, effective, long lasting and highly affordable antimicrobial
protection on the wound care device providing clean barrier protection without
antimicrobial agents entering the body.
NIMBUS is a safe and environmentally sound antimicrobial technology that provides
long-lasting microbial protection at a fraction of the cost of today’s leading
antimicrobials. This technology has all the attributes a consumer products company or
apparel and textile company is looking for, highly effective and permanent, safe and nontoxic,
environmentally friendly, low cost, and no additional capital cost of equipment.
Please contact us at (888) 835-2211 Ext 107 or email: info@quickmedtech.com
About Dr. Gerald M. Olderman
Dr. Olderman is the Vice President of Research & Development and Commercialization
of Quick-Med Technologies, and a member of the Company’s Board of Directors. Dr.
Olderman has over 35 years in the healthcare industry including 31 years in technical
management of product development teams, and 25 years as head of research and
development for major product divisions of three fortune 500 companies. As Vice
President of Research & Development and Commercialization, Dr. Olderman is
responsible for NIMBUS strategic planning and direction of the research & development.
Prior to joining Quick-Med Technologies, Dr. Olderman served as Director and Head of
Research and Development for C.R. Bard, Inc.'s Cardiopulmonary Division, where he
organized a new product development process in which 19 new medical devices were
developed. Dr. Olderman also served as Vice President for Domestic and International
Research and Development for the Pharmaseal Division of Baxter Healthcare Corp. and
Vice President for Research and Development for Converters, a division of American
Hospital Supply Corporation prior to its acquisition by Baxter Healthcare Corporation.
Dr. Olderman held management positions for Johnson and Johnson during his tenure
from 1961-1978 including election to the board of directors of Surgikos as Vice President
of Research & Development in 1975. Dr. Olderman received a B.S in Chemistry from
Rensselaer Polytechnic Institute in New York. He also holds an M.S. and Ph.D. in
Physical Chemistry from Seton Hall University in New Jersey.
About NIMBUS™
The Company’s patented technology, NIMBUS®, employs a family of advanced antimicrobial polymers that destroy bacteria at the cellular level, thereby eliminating the risk of developing drug resistance. Unlike any other microbicide on the market today, the NIMBUS technology works by creating a permanent bond with a multitude of substrates (without leaching) and is less than 10% the cost of silver-based antimicrobials. NIMBUS is highly effective, including against methicillin-resistant Staphylococcus aureus (“MRSA”) and vancomycin-resistant Enterococcus (“VRE”), two of the most significant antibiotic-resistant organisms responsible for hospital infections.
|
